Although also patients with PD-L1 negative tumor may benefit from the treatment with ICIs, high PD-L1 expression in the tumor is assumed as a promising predictive biomarker of response in several solid cancers, including cutaneous melanoma 76-78. The gene discussed is CD274; the disease is cutaneous melanoma.